#news #biotech Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset .Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset
badams
Mon, 03/01/2021 – 09:17

from FierceBiotech: Biotech https://ift.tt/2PnaoW1